Tag:
Santarus
Latest Headlines
Latest Headlines
FDA spurns Pharming's Rhucin app in fresh setback
A few days ago Pharming announced plans for a Phase IIIb study of Rhucin, an experimental therapy produced in transgenic rabbits, in anticipation of running into fresh regulatory challenges. And it
Santarus snags U.S. rights to Pharming's Rhucin in $20M pact
Dutch biotech Pharming will get a much needed shot of cash from a newly inked pact that gives San Diego-based Santarus North American marketing rights to the anti-swelling therapy Rhucin. Pharming
Santarus cuts 120 jobs, focuses on Phase III
San Diego-based Santarus is laying off 120 employees, or 37 percent of its staff. Santarus previously inked a deal with Prasco for an authorized generic of prescription Zegerid, a treatment for
